Lexeo Therapeutics Statistics
Total Valuation
LXEO has a market cap or net worth of $136.11 million. The enterprise value is $24.51 million.
Important Dates
The last earnings date was Monday, March 24, 2025, before market open.
Earnings Date | Mar 24, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
LXEO has 33.20 million shares outstanding. The number of shares has increased by 493.67% in one year.
Current Share Class | 33.20M |
Shares Outstanding | 33.20M |
Shares Change (YoY) | +493.67% |
Shares Change (QoQ) | +0.04% |
Owned by Insiders (%) | 4.46% |
Owned by Institutions (%) | 79.61% |
Float | 21.81M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 1.16 |
P/TBV Ratio | 1.16 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.52, with a Debt / Equity ratio of 0.08.
Current Ratio | 5.52 |
Quick Ratio | 5.32 |
Debt / Equity | 0.08 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -772.01 |
Financial Efficiency
Return on equity (ROE) is -85.37% and return on invested capital (ROIC) is -52.48%.
Return on Equity (ROE) | -85.37% |
Return on Assets (ROA) | -46.11% |
Return on Invested Capital (ROIC) | -52.48% |
Return on Capital Employed (ROCE) | -85.23% |
Revenue Per Employee | n/a |
Profits Per Employee | -$1.37M |
Employee Count | 72 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -73.15% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | -73.15% |
50-Day Moving Average | 4.06 |
200-Day Moving Average | 8.72 |
Relative Strength Index (RSI) | 57.61 |
Average Volume (20 Days) | 931,307 |
Short Selling Information
The latest short interest is 2.22 million, so 6.67% of the outstanding shares have been sold short.
Short Interest | 2.22M |
Short Previous Month | 2.43M |
Short % of Shares Out | 6.67% |
Short % of Float | 10.16% |
Short Ratio (days to cover) | 4.47 |
Income Statement
Revenue | n/a |
Gross Profit | -74.09M |
Operating Income | -105.77M |
Pretax Income | -69.42M |
Net Income | -98.33M |
EBITDA | -105.14M |
EBIT | -105.77M |
Earnings Per Share (EPS) | -$3.09 |
Full Income Statement Balance Sheet
The company has $121.52 million in cash and $9.92 million in debt, giving a net cash position of $111.59 million or $3.36 per share.
Cash & Cash Equivalents | 121.52M |
Total Debt | 9.92M |
Net Cash | 111.59M |
Net Cash Per Share | $3.36 |
Equity (Book Value) | 116.84M |
Book Value Per Share | 3.53 |
Working Capital | 103.28M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$81.15 million and capital expenditures -$481,000, giving a free cash flow of -$81.63 million.
Operating Cash Flow | -81.15M |
Capital Expenditures | -481,000 |
Free Cash Flow | -81.63M |
FCF Per Share | -$2.46 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |